Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.49 |
| ▸ | WNT3A | P56704 | 11/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320672 | 0.88 | WNT3A (0.53) | ABL1DEGS1WNT3AUSP30HDAC1 | |
| SCHEMBL2418638 | 0.86 | DEGS1 (0.43) | ABL1DEGS1WNT3AHDAC1HDAC2 | |
| SCHEMBL2321207 | 0.85 | USP30 (0.52) | ABL1DEGS1WNT3AUSP30HDAC1 | |
| SCHEMBL2323322 | 0.81 | DEGS1 (0.47) | ABL1DEGS1WNT3AHDAC1HDAC2 | |
| SCHEMBL12283692 | 0.81 | USP30 (0.55) | ABL1DEGS1WNT3AUSP30HDAC1 | |
| SCHEMBL2315755 | 0.80 | USP30 (0.52) | ABL1DEGS1WNT3AUSP30HDAC1 | |
| SCHEMBL2317904 | 0.80 | DEGS1 (0.53) | ABL1DEGS1WNT3AUSP30HDAC1 | |
| SCHEMBL2319380 | 0.78 | WNT3A (0.51) | DEGS1WNT3AUSP30HDAC1HDAC2 | |
| SCHEMBL2319121 | 0.78 | NPY5R (0.48) | ABL1DEGS1WNT3AHDAC1HDAC2 | |
| SCHEMBL2317080 | 0.78 | RAB9A (0.56) | DEGS1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | ABL1 985/4885DEGS1 3961/4885WNT3A 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.